<DOC>
	<DOCNO>NCT02031731</DOCNO>
	<brief_summary>This phase I study examine pharmacokinetics safety Onartuzumab ( MetMAb ) chinese patient locally advance metastatic solid tumor . Patients divide 3 cohort , give different dose MetMAb . The cohort treat sequentially , start low dose . MetMAb administer intravenously every 3 week . Patients may treat 16 cycle ( 21 day ) 1 year , whichever occur first , absence disease progression .</brief_summary>
	<brief_title>The Pharmacokinetics Safety Onartuzumab ( MetMAb ) Chinese Patients With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age &gt; /= 18 year Histologically confirm locally advanced metastatic solid tumor respond standard treatment standard treatment . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . Use effective contraception Life expectancy &gt; 3 month Brain metastasis spinal cord compression yet definitively treat surgery and/or radiation , and/or patient brain metastasis receive corticosteroid . Previously diagnose treated central nervous system ( CNS ) metastases spinal cord compression clinically stable least 2 month . Treatment antitumor therapy within 4 week start study treatment , follow exception : Patients metastatic prostate cancer maintenance hormonal therapy , provide meet eligibility criterion . Current , serious uncontrolled , systemic illness . Recent stroke ( within past 6 month ) . Active autoimmune disease control nonsteroidal antiinflammatory drug ( NSAIDs ) . History cardiovascular condition . Any disease , gastrointestinal abnormality , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication . Receipt investigational agent , participation clinical study , within 4 week start study treatment . Major surgery within 4 week start study treatment , without complete recovery . Significant traumatic injury within 3 week start study treatment ( All wound must fully heal prior Day 1 ) . Uncontrolled excess calcium level . Known human immunodeficiency virus ( HIV ) infection . Inadequate organ function Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>